Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants are assigned to one of two biomarker-defined cohorts based on tumor antigen expression: (A) Mesothelin (MSLN) and/or MUC1, or (B) Claudin 18.2 (CLDN18.2) and/or MUC1. The study uses a dose-escalation followed by dose-expansion design to define a recommended Phase 2 dose (RP2D) and to estimate response rates in each cohort.

Trial Details

NCT ID

NCT07480928

Phase

PHASE1 / PHASE2

Sponsor

Beijing Biotech

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)
EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)
Lymphodepleting chemotherapy (Flu/Cy)

Locations (sample)

Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

Age 18 to 75 years at the time of consent.
Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC).
Unresectable locally advanced or metastatic disease with progression after at least 1 prior standard systemic therapy regimen, or intolerance/ineli…
At least 1 measurable lesion per RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →